10/16/23 Health Advisory: FDA Authorized New Novavax COVID-19 Vaccine Formulation

  • On Oct. 3, 2023, U.S. Food and Drug Administration (FDA) authorized for emergency use a new adjuvanted (2023–2024) formulation of Novavax COVID-19 vaccine for people 12 years or older.
    • The new formulation better protects against currently circulating COVID-19 variants.
    • Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) includes this new formulation in its 2023–2024 COVID-19 recommendations.
  • FDA deauthorized the original Novavax COVID-19 vaccine.

The new adjuvanted (2023–2204) formulation of Novavax COVID-19 vaccine is authorized for people 12 years or older as follows:

  • Previously received any COVID-19 vaccine—May get 1 dose of the new formulation, at least 2 months after their last dose of COVID-19 vaccine.
  • Never previously received any COVID-19 vaccine—May get 2 doses of the new formulation, separately administered 3 weeks apart.
  • Immunocompromised people—May get an additional dose of the new formulation, at least 2 months after their last dose of the new formulation. Administer additional dose at the healthcare provider’s discretion, with the timing based on the person’s clinical circumstances. 

Updated 2023–2024 COVID-19 vaccine availability may be limited and vary by location. Help patients understand this situation and thank them for their patience.

Resources

Questions?

Call Grays Harbor County Public Health at (360) 532-8631, Monday–Friday, 8 a.m.–4:30 p.m. After hours, call Duty Officer phone for immediately notifiable conditions at (360) 581-1401.